Ohmyhome Reports 118% Revenue Growth for Fiscal Year 2024
Financial Performance: Ohmyhome Ltd. reported a total revenue increase of 118% to S$10.9 million for the fiscal year ending December 31, 2024, with significant growth in all business segments and a narrowed net loss of S$4.4 million.
Operational Highlights: The company improved its gross margin to 40.5%, reduced EBITDA loss to S$3.4 million, and strengthened shareholders' equity from S$4.0 million to S$6.3 million, while focusing on scaling core businesses through enhanced marketing and AI engagement strategies.
Trade with 70% Backtested Accuracy
Analyst Views on OMH
About OMH
About the author
OM Holdings (ASX:OMH) Shares Plunge 64% Over Three Years Amid EPS Loss
- Poor Stock Performance: OM Holdings' share price has plummeted by 64% over the past three years, reflecting significant challenges faced by the company that have undermined long-term investor confidence.
- Short-term Losses Intensify: In the last year alone, OM Holdings' stock has dropped by 29%, indicating that new investors are also experiencing severe financial difficulties, which could impact future financing capabilities.
- Declining Profitability: Concurrent with the stock price decline, OM Holdings' earnings per share (EPS) has significantly fallen, even resulting in a loss, making EPS a less reliable metric for assessing company performance.
- Market Performance Comparison: While the overall market gained about 10%, OM Holdings investors faced a total loss of 28%, suggesting a weakening competitive position and diminishing market confidence in the company.
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Analyst Downgrades: Several Wall Street analysts have downgraded their ratings on various stocks, including Packaging Corporation of America (from Buy to Hold), Sarepta Therapeutics (from Neutral to Sell), and Angi Inc. (from Market Outperform to Market Perform).
Price Target Adjustments: Along with downgrades, analysts have also lowered price targets for these companies, with notable reductions for Sarepta Therapeutics from $40 to $10 and PROS Holdings from $27 to $18.
